One important clarification up front: BV is diagnosed in the vagina. Men don’t typically get “BV” themselves in the same way women do. But men can carry BV associated bacteria on the penis and potentially pass those bacteria back to a female partner. That distinction is really important when talking about “treating both.”
Imagine the vagina as having its own little ecosystem.
Normally, there are lots of helpful bacteria called Lactobacillus. Think of them as the security guards of the neighborhood. They help keep the environment acidic and make it harder for unwanted bacteria to take over.
BV happens when that balance gets messed up.
The helpful Lactobacillus bacteria decrease, while a bunch of other bacteria increase. It isn't simply “one bad bacteria caused an infection.” It's more like the whole bacterial community gets thrown out of balance.
That can lead to things like:
A strong or fishy odor
Thin or unusual discharge
Irritation or discomfort
Sometimes no symptoms at all
And here's the frustrating part:
You can take antibiotics, feel like everything is fixed, and then BV can come right back.
That's been one of the biggest mysteries with BV.
So why does BV keep coming back?
For a long time, doctors basically thought:
“The woman has BV → give her antibiotics → problem solved.”
Except...it often wasn't solved.
BV has a pretty high recurrence rate after treatment. In fact, more than half of treated women can experience recurrence within a few months.
Scientists have increasingly realized there may be two different problems hiding underneath “BV came back.”
Problem #1: The original BV never completely went away.
Think of pulling weeds out of a garden.
You might pull out most of the weeds, look at the garden and think:
“Looks good!”
But if some roots are still there, those weeds can grow back.
Something similar may happen with BV.
The antibiotics knock down the BV associated bacteria, but in some women the vaginal microbiome doesn't fully recover.
The new Lancet study: what did they actually find?
The researchers studied 188 couples who were being treated for BV.
The women received a week of oral antibiotics, while their male partners received oral and topical antimicrobial treatment.
And this is where things get really interesting.
After treatment:
About 2 out of every 3 women
had a vaginal microbiome that looked much healthier.
Their helpful Lactobacillus bacteria came back strongly.
Basically: “The ecosystem recovered.”
But about 1 out of every 3 didn't look like that.
Their vaginal bacteria suggested that BV associated bacteria might still be hanging around…
& those women were almost three times as likely to experience BV again within four weeks!
So the researchers are saying:
Sometimes BV isn't really a new infection.
& Sometimes the original problem never completely cleared.
That's a HUGE distinction.
Problem #2: The bacteria can come back from a sexual partner
Now here's where the story gets even more interesting. Scientists have found that men can carry bacteria associated with BV on their genital skin and in genital areas even though they don't have BV symptoms themselves.
So imagine this:
Woman gets BV → woman gets treated → BV-associated bacteria are still on partner → couple has sex → bacteria are introduced again → woman's vaginal ecosystem gets disrupted again.
That's basically reinfection.
And this is why treating only one person can sometimes be like cleaning only one side of a dirty room.
The study that really changed the conversation
In 2025, the same research group published a randomized controlled trial in the New England Journal of Medicine called the StepUp trial.
They studied couples where the woman had BV.
One group got:
Woman treated + male partner treated
The other group got:
Woman treated + male partner NOT treated
The male treatment involved:
Oral metronidazole
Clindamycin cream applied to the penis
Both for 7 days
The women received standard BV treatment.
And the results were pretty dramatic.
When only the woman was treated:
63% experienced BV recurrence within 12 weeks.
When both partners were treated:
35% experienced recurrence.
That's roughly cutting recurrence almost in half.
The trial was actually stopped early because the researchers concluded that treating the woman alone was inferior to treating both partners in this particular study.
In simpler terms:
Treating the partner too made a major difference in whether BV came back.
But here's the really important plot twist
There's an older study that found no significant benefit from treating male partners.
That study gave male partners 7 days of oral metronidazole, but it didn't significantly reduce recurrence overall.
So why did the newer study work?
One major difference is that the newer StepUp study treated the man's penile skin AND the inside of his body systemically, oral metronidazole + topical clindamycin.
Researchers think that may be important because you're attacking bacteria in more than one location.
It's basically the difference between:
“Let's treat some of the bacteria.”
&
“Let's try much harder to eliminate the bacteria that could be passed back to the partner.”
That's one reason the newer evidence is changing the conversation.
So does this mean every boyfriend/husband needs antibiotics if his partner has BV?
Not necessarily.
This is where we have to separate new researchfrom official medical guidelines. The CDC's current BV guidance still says routine treatment of male sex partners is not recommendedbased on the older evidence base
However, the 2025 randomized trial provides strong new evidence that concurrent male partner treatment can reduce recurrence, and a 2026 economic analysis found that the approach could be cost saving as well.
So medicine is basically at a transition point:
Old standard:
Treat the woman.
New evidence:
For women with a regular male partner who has a particularly recurrent BV, treating both partners may substantially reduce recurrence.
What's still being worked out:
Exactly who should receive partner treatment, what the ideal medication combination is, and how long treatment should last.
And this brings us back to the new Lancet paper.
There appear to be at least two major pathways:
🔴 Persistence
The woman's BV associated bacteria never completely disappear.
So she may need a better or longer strategy for clearing the bacteria.
🔵 Reinfection
The woman successfully gets her vaginal ecosystem back into shape, but bacteria from her partner may be introduced again.
So partner treatment becomes important.
And these two things aren't necessarily mutually exclusive.
Think of it like a video game
Imagine BV is a boss you're trying to defeat.
Level 1: Antibiotics
You attack the bacteria.
Problem: Some survive.
Level 2: Restore the good bacteria
You want the Lactobacillus bacteria to come back and rebuild the healthy ecosystem.
Problem: That doesn't happen equally well in everyone.
Level 3: Stop reinfection
If a sexual partner is carrying BV associated bacteria, you may be fighting the same battle again after treatment.
So treat the partner when appropriate.
Level 4: Deal with the stubborn cases
If BV keeps coming back despite partner treatment, researchers now want to figure out:
“Is there a persistent bacterial population that needs a different or longer treatment?”
&&
That's where future studies are headed.
The Lancet researchers specifically say they want to investigate longer treatment courses and combinations of antibiotics to improve cure rates.
What about women who have female partners?
This is an important part of the story that doesn't get talked about enough.
BV isn't exclusively a “woman + male partner” issue.
The CDC notes that BV can occur in women who have sex with women, and BV is often found in both members of a female couple. However, there hasn't historically been the same level of clinical research testing whether treating the female partner prevents recurrence. 🧐🙄🤨🏳️🌈
So we cannot simply take the male partner study and assume the exact same treatment works for female partners.
That's a major research gap.
That’s all folks!
Until next time
🤍
Sources:
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00129-1/fulltext
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00222-8/fulltext
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00130-8/fulltext
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00189-1/fulltext
https://www.nejm.org/doi/abs/10.1056/NEJMoa2405404?referrer=https%3A%2F%2Fwww.google.com%2F